Oestrogens play an important role in the development and progression of papillary thyroid carcinoma (PTC) through oestrogen receptor (ER)-a and -b, which may exert different or even opposing actions in PTC. The roles of ERb in ERa-negative PTC are still not clear. This study investigated the expression dynamics of ERb1 (wildtype ERb) and its clinical significance in female ERa-negative PTC patients. ERb1 expression was detected in thyroid tissues of 136 female patients diagnosed with PTC. The relationships between ERb1 expression and clinicopathological/biological factors were also analysed in female ERa-negative PTC patients. The total score for ERb1 was significantly lower in female ERa-negative PTC patients with LNM or ETE when compared to those without LNM or ETE (Z = À2.923, P = 0.003 and Z = À3.441, P = 0.001). Accordingly, the total score for ERb1 was significantly higher in ERa-negative PTC patients expressing E-cadherin compared to patients negative for E-cadherin expression (Z = À2.636, P = 0.008). The total score was lower in ERa-negative PTC patients positive for VEGF expression compared to those negative for VEGF expression (Z = À1.914, P = 0.056). This preliminary study indicates that reduced expression of ERb1 in female ERa-negative PTC patients is associated with greater progression of the disease. This may provide insights into the underlying molecular mechanisms of ERb1 and could help design targeted approaches for treating or even preventing this disease.
Introduction
Thyroid cancer is the most common endocrine malignancy. The incidence of papillary thyroid cancer (PTC) in particular has increased worldwide over the last few decades (La Vecchia et al. 2015; Lim et al. 2017) . According to recent cancer statistics in China, thyroid cancer is the eighth most common cancer in Chinese women, and its incidence is increasing. Thyroid cancer occurs three times more frequently in women than in men (Chen et al. 2016) . This female predominance and the predilection of thyroid cancer to afflict postpubertal and premenopausal women suggest that oestrogen might play a role in the development and growth of thyroid cancer. However, no significant molecular or genetic factors explaining this gender disparity have been identified (Enewold et al. 2009; Nagataki & Nystr€ om 2002) .
Oestrogen binds to oestrogen receptors (ERs). Activated ERs bind DNA and regulate the expression of many different target genes. ERs are encoded by two distinct genes: ERa (ESR1) and ERb (ESR2). Several splice variants of ERb have been identified, which are either exon deletions or products of alternative splicing that code for proteins truncated at the C-terminus that do not bind the oestrogen ligand. ERb1 (wild-type ERb) is the only fully functional isoform that can bind oestrogen. ERa and ERb act in distinct ways in several oestrogen target cells, including PTC tissues. Specifically, ERa exerts proliferative, antiapoptotic, autophagic and metastatic effects in PTC cells, whereas ERb has differentiation-inducing and pro-apoptotic effects (Dong et al. 2013; Fan et al. 2015; Zeng et al. 2008) . Both receptors have been described in both neoplastic and nonneoplastic human thyroid tissues with extremely variable results (Ahn et al. 2015; Ceresini et al. 2006; Dong et al. 2012; Eldien et al. 2017; Fan et al. 2015; Huang et al. 2014; Magri et al. 2012; Sturniolo et al. 2016; Vaiman et al. 2010; Vannucchi et al. 2015) . ERa is detectable in PTC tissues with positive percentages ranging from 9.9% to 66.5% (Ahn et al. 2015; Eldien et al. 2017; Fan et al. 2015; Huang et al. 2014; Magri et al. 2012; Sturniolo et al. 2016; Vannucchi et al. 2015) . However, ERb expression is more frequently found with positive percentages ranging from 44.4% to 97.8% (Ahn et al. 2015; Ceresini et al. 2006; Dong et al. 2012; Huang et al. 2014; Magri et al. 2012; Vaiman et al. 2010) . It is important to note that there are two groups of ERb-positive PTC: those that co-express both ERa and ERb, and those expressing ERb only. There are accumulating studies that investigated the level and frequency of expression of ERb1 and its association with clinicopathological parameters, established markers of prognosis and clinical outcome in ERa-negative breast carcinoma (Chantzi et al. 2013; Gruvberger-Saal et al. 2007; Honma et al. 2008; Novelli et al. 2008; Poola et al. 2005; Reese et al. 2014; Skliris et al. 2006) . However, previous studies focused on the expression and clinical significance of ERb in PTC without regard for the expression of ERa. They explored the expression of ERb protein and its association with important clinicopathological factors (e.g. tumour size), disease outcomes and biological markers (e.g. Ki-67) by immunohistochemical (IHC) or quantitative analyses of the associations between ESR1 and ESR2 gene expression levels, the ESR1/ESR2 ratio and the clinicopathological characteristics of PTC patients using data from the Cancer Genome Atlas (TCGA) (Ahn et al. 2015; Huang et al. 2014; Yi et al. 2017) . However, there are little data exploring PTCs that express ERb alone. Thus, the roles of ERb1 in ERa-negative PTC remain unknown. In this study, we examined the expression dynamics and clinical significance of ERb1 in female ERa-negative PTC patients.
Materials and methods

Patients and tissue specimens
Thyroid tissue specimens were obtained from 136 female Chinese PTC patients. The mean age of the patients was 43.38 years old (range, 18-79 years). All of these patients were admitted to our hospital for a standard thyroidectomy between 2008 and 2013. Their diagnoses were confirmed by histopathological examination. None of these patients had a family history of thyroid cancer or external neck irradiation. Clinicopathological data, such as age at diagnosis, menopausal status, tumour size, lymph node metastasis (LNM) and the presence of extrathyroidal extension (ETE), were retrieved from the patients' medical records. ETE was defined as gross extrathyroidal invasion of the subcutaneous soft tissues, larynx, trachea, oesophagus, recurrent laryngeal nerve and prevertebral fascia encasing the carotid artery or mediastinal vessels from a tumour of any size (Tuttle et al. 2016) . The cancer stage was defined according to the 8th edition of the tumour, node and metastasis system classification by the American Joint Committee on Cancer (Tuttle et al. 2016) . The study protocol was performed according to the Declaration of Helsinki and approved by the Medical Ethics Committee of China Medical University (AF-S0P-07-1.0-01). Written and verbal informed consent was obtained from all participants.
Immunohistochemistry (IHC)
IHC staining was performed to analyse the expression of ERa, ERb1, Ki-67, E-cadherin and VEGF in PTC as previously described (Huang et al. 2014) . Briefly, IHC was conducted on formalin-fixed and paraffin-embedded sections (4 lm thick) of surgical specimens from PTC patients using the Elivision TM plus two-step system (Maxim Biotech Inc., Fuzhou, China). This method has proven superior to biotinbased SP and ABC detection systems due to the presence of large amounts of endogenous biotin in the thyroid (Huang et al. 2014; Kanehira et al. 2008) . The tissue sections were deparaffinized, rehydrated and subjected to microwave antigen retrieval in 10 mM citrate buffer (pH 6.0) for 20-25 min. Endogenous peroxidase was then blocked using 3% H 2 O 2 for 10 min. After washing three times in phosphatebuffered saline (PBS), the sections were incubated with a primary antibody against ERa (Clone 1D5, Dako; 1:200), ERb1 (Clone PPG5/10, Serotec; 1:20), Ki-67 (Clone SP6, Abcam; 1:100), E-cadherin (Clone HECD-1, Abcam; 1:100) or VEGF (Clone EP1176Y, Abcam; 1:100) in a humidified chamber at 4°C overnight. Staining was performed according to the manufacturer's instructions. Colour reactions were performed using 3,3 0 -diaminobenzidine (DAB; Maxim Biotech Inc.). The sections were then counterstained with haematoxylin, washed, dehydrated into alcohol, cleared in xylene and mounted with coverslips. Appropriate positive and negative controls were run simultaneously with the patient specimens. Negative control staining was performed using normal rabbit or mouse IgG in place of a specific primary antibody.
Review and scoring of stained tissue sections
Immunostained tissue sections were reviewed, scored and interpreted using the Allred score as previously described (Huang et al. 2014) . In brief, each section was carefully evaluated under the light microscope. A proportion staining score (PS) was assigned, which represented the estimated International Journal of Experimental Pathology, 2018, 99, 15-21 proportion of positive-staining tumour cells as follows: 0, no staining; 1, <1/100; 2, 1/100 to 1/10; 3, 1/10 to 1/3; 4, 1/3 to 2/3; and 5, >2⁄3. An intensity score (IS) was also assigned to represent the average intensity of positive tumour cells in each section as follows: 0, no staining; 1, weak; 2, intermediate; and 3, strong. Finally, a total score (TS) was calculated from the sum of PS and IS (ranging from 0, 2-8). 'Positive' staining was defined as any score ≥3. A double-blind analysis was performed by two independent investigators (Wang ZH and Sun W). If discrepancies occurred, a third investigator (Dong WW) evaluated the tissue sections, and the common result was used.
Statistical analysis
Descriptive statistics was used based upon the distribution of variables. The Mann-Whitney U test was used to compare quantitative variables between groups. The chi-square test or Fisher's exact test was used to compare qualitative variables between groups. All statistical analyses were performed using SPSS software, version 17.0 (SPSS Inc., Chicago, IL, USA). Differences were considered statistically significant if P < 0.05.
Results
Expression of ERb1 protein in female ERa-negative PTC patients
In this study, we first examined ERa expression in 136 cases of PTC tissue specimens using IHC. ERa was detected in 48.5% (66/136) of all PTC patient samples. Next, we selected the 70 samples that were ERa-negative for further study. Of these samples, 95.7% were positive for ERb1. Nuclear expression only, both nuclear and cytoplasmic expression, and cytoplasmic expression only for ERb1 protein were observed in 15.7%, 65.7% and 14.3% of samples respectively. The staining score frequencies of ERb1 in 70 cases of PTC tissue specimens were Score 0 (three cases, 4.3%), Score 3 (two cases, 2.9%), Score 4 (three cases, 4.3%), Score 5 (14 cases, 20.0%), Score 6 (18 cases, 25.7%), Score 7 (24 cases, 34.3%) and Score 8 (six cases, 8.6%). Representative images are shown in Figure 1 .
Relationships between ERb1 expression and clinicopathological factors of female ERa-negative PTC patients
In female ERa-negative PTC patients, no significant difference was observed for the incidence of ERb1 expression after examining the total scores and subcellular distributions of ERb1 and comparing this data to ages at diagnosis (<55 years vs. ≥55 years), menopausal status (pre-vs. postmenopausal), tumour size (≤20 mm vs. >20 mm) or TNM stage (I/II vs. III/IV). The total score of ERb1, but not the positive percentage or subcellular distribution, was significantly decreased in ERa-negative female PTC patients with LNM or ETE compared to the corresponding patients without LNM or ETE (Z = À2.923, P = 0.003 and Z = À3.441, P = 0.001) ( Table 1) .
Relationships between ERb1 expression and biological markers in female ERa-negative PTC patients
The expression of Ki-67, E-cadherin and VEGF in PTC lesions is examined as shown in Figure 2 . As a cell proliferation-associated antigen, Ki-67 is expressed in the nuclei of PTC cells and has been found to be a marker for cell proliferation and a prognostic factor for both disease-free survival (DFS) and cause-specific survival (CSS) in PTC patients (Ito et al. 2014; Pan et al. 2017) . However, there was no significant difference of Ki-67 expression between patients with tumour size ≤2 cm and >2 cm (Z = À0.309, P = 0.757). As a transmembrane glycoprotein, E-cadherin is involved in cell-cell adhesion and epithelial-mesenchymal transition (EMT). Loss of E-cadherin expression at primary tumour sites has been associated with increased rates of metastasis and poor patient outcomes of various malignant tumours, including gastric carcinomas, breast carcinoma and nonsmall cell lung carcinoma (Mitchell et al. 2016 ). E-cadherin was detected at the cell membrane in PTC lesions, and loss of its expression was reported to be an independent prognostic factor for PTC (Erdem et al. 2011; von Wasielewski et al. 1997) . We found E-cadherin expression was significantly lower in patients with ETE or LNM than that in those patients without ETE or LNM (Z = À2.505, P = 0.012 and Z = À2.420, P = 0.016). VEGF is a well- Figure 1 Immunohistochemical staining of ERb1 in PTC lesions. Formalin-fixed and paraffin-embedded PTC tissue sections were stained with the Elivision TM plus two-step system and specific antibodies against ERb1. PTC tissues showed typical staining patterns of nuclear ERb1 staining (a), nuclear and cytoplasmic ERb1 staining (b),cytoplasmic ERb1 staining (c) and negative control (d) (magnification 9400). [Colour figure can be viewed at wileyonlinelibrary.com] PTC, papillary thyroid cancer; LNM, lymph node metastases; ETE, extrathyroidal extension; TNM stage, tumour node metastasis stage; n, number of patients. Nu, exclusively nuclear staining; Nu + Cyto, combined nuclear and cytoplasmic staining; Cyto, exclusively cytoplasmic staining. a Total score was calculated from the sum of the proportion staining score and intensity score to reflect the expression level, which is given as the mean AE S.D. Figure 2 Immunohistochemical staining of Ki-67, E-cadherin and VEGF in PTC lesions. Formalin-fixed and paraffin-embedded PTC tissue sections were stained with the Elivision TM plus two-step system and specific antibodies against Ki-67, E-cadherin and VEGF. PTC tissues showed typical staining patterns of Ki-67 (a), E-cadherin (b) and VEGF (c) and negative control (d) (magnification 9400). [Colour figure can be viewed at wileyonlinelibrary.com] PTC, papillary thyroid cancer; Nu, exclusively nuclear staining; Nu + Cyto, combined nuclear and cytoplasmic staining; Cyto, exclusively cytoplasmic staining. a Total score was calculated from the sum of the proportion staining score and intensity score to reflect the expression level, which is given as the mean AE S.D.
(a) (b) (c) (d)
International Journal of Experimental Pathology, 2018, 99, 15-21 known pro-angiogenic factor and may be an important biological marker that determines the angiogenic and lymphangiogenic potentials of PTC cells. VEGF negatively correlates with disease-free cancer mortality and recurrence (Hsueh et al. 2011; Klein et al. 2001) . Similarly, cytoplasmic localization of VEGF was observed in PTC tissues. We found patients with ETE, but not LNM, had significantly higher VEGF expression than those patients without these clinical features (Z = À3.235, P = 0.001). In our study, no difference was found in the incidence of ERb1-positive patients or the subcellular distribution of ERb1 in ERa-negative PTC patients positive for Ki-67, E-cadherin or VEGF expression compared to the corresponding patients who were negative for these factors. However, the total score for ERb1 was significantly higher in ERa-negative PTC patients expressing Ecadherin compared to the corresponding patients negative for E-cadherin (Z = À2.636, P = 0.008). Meanwhile, the score for ERb1 was lower in ERa-negative PTC patients positive for VEGF expression compared to the corresponding patients negative for VEGF expression (Z = À1.914, P = 0.056) ( Table 2) .
Discussion
To our knowledge, this is the first study of the expression profiles of ERb1 protein and its association with clinicopathological factors/biological markers in female ERa-negative PTC patients. Our results revealed that the majority of PTC tissues were positive for ERb1 expression, and these tissues predominantly displayed nuclear and cytoplasmic localization for ERb1. PTC patients with highly aggressive clinicopathological features (e.g. LNM or ETE) had lower expression of ERb1 protein than the corresponding patients without those features. Accordingly, the expression of ERb1 positively correlated with E-cadherin expression and negatively correlated with VEGF expression. These findings indicated that reduced expression of ERb1 was associated with tumour invasion and metastasis in female ERa-negative PTC patients. The constitutive expression of ERb1 may still play a tumour-suppressive role independently even in cases where ERa expression is lost in PTC. The associations of ERb1 expression with tumour progression and disease outcomes have been explored in some oestrogen-related tumours, especially breast cancer. Some studies showed that ERb1 protein expression correlated with less aggressive behaviour and good disease-free and overall survival in breast cancer (Rosin et al. 2014; Sugiura et al. 2007 ). However, ERb1 was not considered as a prognostic or predictive biomarker for breast cancer using extensive survival analyses in four large cohorts of human breast cancer patient (Wimberly et al. 2014) . This discrepancy might be because they did not take the subcellular localization and the status of ERa into consideration. Thus, further studies showed nuclear ERb1 was associated with low histological grade and an independent marker of lower rates of recurrence in patients with HER2-positive and triple-negative tumours treated with tamoxifen monotherapy (Chantzi et al. 2013; Honma et al. 2008) . In this study, we found total score, but not positive percentage or subcellular localization, of ERb1 was associated with clinicopathological parameter. That is, reduced expression of ERb1 was associated with LNM and ETE in female ERa-negative PTC patients, suggesting the antitumour activity of ERb1 in this type of PTC. Moreover, we found that there was no difference of ERb1 expression and its associations with clinicopathological factors/biological markers between ERa-positive and ERa-negative tumours in PTC (data not shown). Thus, a novel line of ERb1 targeted drugs could be designed to treat ERa-negative tumours similar to ERa blockers for ERa-positive tumours.
Recently, some studies have focused on IHC markers and evaluated the expression of Galectin-3, Ki-67, E-cadherin and VEGF in PTC (Erdem et al. 2011; Hsueh et al. 2011; Ito et al. 2014; Tang et al. 2016) . These proteins have been considered useful markers reflecting the biological behaviour and prognosis for PTC. In this study, we analysed the associations between ERb1 expression and the expression of Ki-67, E-cadherin and VEGF. There is increasing evidence suggesting that there is an association between Ki-67 expression and outcomes of PTC (Ito et al. 2014; Matsuse et al. 2017; Pan et al. 2017) . In this study, we did not find an association between ERb1 and Ki-67, which was consistent with our previous findings (Huang et al. 2014) . The involvement of ERb1 in proliferation in ERa-negative breast cancer is also unclear. Skliris et al. reported that ERb1 positively correlates with Ki-67 in ERa-negative breast cancer, suggesting that ERb1 expression in ERa-negative breast cancer is associated with a high proliferative index (Skliris et al. 2006) . However, in another constitutive ERb overexpression model, little or no effect of ERb on proliferation occurs in MDA-MB-231 cells, an ERa-negative breast cancer cell line (Rousseau et al. 2004) . It is believed that reduced expression of E-cadherin causes a loss of cell adhesion, leading to excessive proliferation, cancer progression and increased metastatic potential. Reduced expression of E-cadherin in PTC correlates with capsule invasion, LNM, multiple foci, a tumour diameter of >10 mm and poor prognosis (Ceyran et al. 2015; Scheumman et al. 1995) . In our study, reduced expression of E-cadherin also correlates with ETE and LNM. ERb1 expression significantly positively correlates with E-cadherin expression. These findings indicated that ERb may have suppressive effects on the ETE and LNM of PTC, and E-cadherin may be involved in this process. Our previous study also suggested that DPN inhibits the migration and invasion of human PTC cell line BCPAP, which is modulated by E-cadherin. This molecular mechanism has also been demonstrated in breast cancer. ERb1 inhibits the migration and invasion of breast cancer cells through upregulation of E-cadherin in an Id1-dependent manner (Zhou et al. 2015) . Downregulation of ERb increases the expression levels of the epithelial marker E-cadherin and cell junctions, followed by a reduction in various cell behaviours, such as proliferation, migration, spreading capacity, invasion and adhesion to collagen I (Piperigkou et al. 2016) . Members of the VEGF family are key stimulators of both angiogenesis and lymphangiogenesis, which are fundamental processes for tumour progression. VEGF, also known as VEGF-A, is a critical regulator of tumour angiogenesis, and it induces proliferation, migration, invasion and endothelial cell survival. VEGF expression is upregulated in PTC, and it correlates with the pathological parameters and metastatic status of PTC (Erdem et al. 2011; Salajegheh et al. 2013; Tian et al. 2008) . Therefore, regulation of VEGF is a way to modulate tumour progression in PTC. In our study, increased expression of VEGF correlates with ETE, but not LNM. ERb1 expression negatively correlates with VEGF expression. These findings indicate that ERb may inhibit tumour invasion of PTC, and VEGF may be involved in this process. Our previous study suggested that both the incidence and total score for VEGF expression are significantly decreased in female PTC patients of reproductive age with exclusively nuclear ERb1 expression compared with those with extranuclear localization of ERb1. This suggests that oestrogen may suppress VEGF expression through transcriptional effects mediated by ERb1 when it localizes to the nuclei of PTC cells. This molecular mechanism has also been demonstrated in some other malignant tumours. ERb attenuates the hypoxic induction of VEGF mRNA by directly inhibiting the binding of HIF-1a to the VEGF promoter in breast cancer (Lim et al. 2011) . Treatment of DPN reduces VEGF expression, and cotreatment with the ERbspecific antagonist PHTPP abrogates this effect in PC3 prostate cancer cells (Park & Lee 2014) .
This study has characterized the expression and clinical significance of ERb1 in female ERa-negative PTC patients. The association of ERb1 expression with LNM, ETE, E-cadherin and VEGF expression suggests that ERb1 may exert inhibitory effects on tumour invasion and metastasis in PTC patients, and E-cadherin and VEGF may be involved in this process. This has clinical implications for selective targeting of ERb1 for therapeutic and preventative strategies against ERa-negative PTC. However, we recognize that the limitations of this study relate to the relatively small number of cases we examined and missing information regarding patient outcomes. Thus, the potential clinical significance of ERb1 in female ERa-negative PTC patients is worth considering, but these results should be confirmed in a larger number of patients under long-term follow-up.
